Drug Approval | September 26, 2025
FDA approves Alembic’s Paroxetine ER tablets
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities
BIL also holds an option to increase its equity stake by an additional 15%
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
The CSR initiative will offer Digital Radiology X-Ray service to Dholera and 33 surrounding villages in the region
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
Ultra-high purity surfactant for biologics and parenteral drug formulations
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Relonchem receives marketing authorization for Moxonidine tablets
Subscribe To Our Newsletter & Stay Updated
